• Fangyuan Zhang, Chunwai Wong, Yida Chiu, Joie Ensor, Mohamed O Mohamed, George Peat, and Mamas A Mamas.
• Keele Cardiovascular Research Group, Centre for Prognosis Research, Institutes of Applied Clinical Science and Primary Care and Health Sciences, Keele University, Keele, UK.
• Int. J. Clin. Pract. 2021 Oct 1; 75 (10): e14345.

AimTo identify existing comorbidity measures and summarise their association with acute coronary syndrome (ACS) outcomes.MethodsWe searched published studies from MEDLINE (OVIDSP) and EMBASE from inception to March 2021, studies of the pre-specified conference proceedings from Web of Science since May 2017, and studies included in any relevant systematic reviews. Studies that reported no comorbidity measures, no association of comorbid burden with ACS outcomes, or only used a comorbidity measure as a confounder without further information were excluded. After independent screening by three reviewers, data extraction and risk of bias assessment of each included study was undertaken. Results were narratively synthesised.ResultsOf 4166 potentially eligible studies identified, 12 (combined n = 6 885 982 participants) were included. Most studies had a high risk of bias at quality assessment. Six different types of comorbidity measures were identified with the Charlson comorbidity index (CCI) the most widely used measure among studies. Overall, the greater the comorbid burden or the higher comorbidity scores recorded, the greater was the association with the risk of mortality.ConclusionThe review summarised different comorbidity measures and reported that higher comorbidity scores were associated with worse ACS outcomes. The CCI is the most widely measure of comorbid burden and shows additive value to clinical risk scores in use.© 2021 The Authors. International Journal of Clinical Practice published by John Wiley & Sons Ltd.

6 keywords...

hide…